Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
12MP + 6MHP
- Development stage
- Unknown
- Lead developer
- University of Virginia
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
A multipeptide melanoma vaccine combination consisting of twelve MHC class I-restricted melanoma peptides (12MP) and six MHC class II-restricted melanoma helper peptides (6MHP). The 12MP component is designed to stimulate CD8+ cytotoxic T lymphocyte (CTL) responses against shared melanoma antigens, including gp100, MART-1, Tyrosinase, MAGE-A1, MAGE-A3, and NY-ESO-1. The 6MHP component provides cognate CD4+ T cell help, which is hypothesized to enhance the development and durability of circulatory memory CD8+ T cells. Clinical data from the Mel44 trial (NCT00118274) demonstrated that patients receiving the 12MP + 6MHP combination had improved long-term clinical outcomes and better preservation of memory CD8+ T cells compared to those receiving 12MP with a non-cognate tetanus helper peptide.
- Other names
- 12MP + 6-methylmercaptopurine12MP + six melanoma helper peptides12MP + 6MHP vaccine
02
Targets
MAGEA1 (Melanoma-associated antigen 1)Melanoma-associated antigen 3-derived peptide epitopesMHC II (Major histocompatibility complex class II receptor)TYRP (Tyrosinase-derived melanoma peptide epitopes)Glycoprotein 100-derived melanoma peptide epitopesNY-ESO-1 (New york esophageal squamous cell carcinoma 1)MHC I (MHC class I})MLANA (Melanoma antigen recognized by T cells 1)
Beyond the preview
Go deeper on 12MP + 6MHP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 12MP + 6MHP.